Cure of Alzheimer’s Dementia in Many Patients by Using Intranasal Insulin to Augment an Inadequate Counter-Reaction, Edaravone to Scavenge ROS, and 1 or 2 Other Drugs to Address Affected Brain Cells

The goal of treatment for Alzheimer’s dementia (AD) is the restoration of normal cognition. No drug regimen has ever achieved this. This article suggests that curing AD may be achieved by combination therapy as follows. First, with intranasal insulin to augment the body’s natural counter-reaction to...

Full description

Bibliographic Details
Main Author: Jeffrey Fessel
Format: Article
Language:English
Published: MDPI AG 2023-04-01
Series:Journal of Clinical Medicine
Subjects:
Online Access:https://www.mdpi.com/2077-0383/12/9/3151
_version_ 1797602284544196608
author Jeffrey Fessel
author_facet Jeffrey Fessel
author_sort Jeffrey Fessel
collection DOAJ
description The goal of treatment for Alzheimer’s dementia (AD) is the restoration of normal cognition. No drug regimen has ever achieved this. This article suggests that curing AD may be achieved by combination therapy as follows. First, with intranasal insulin to augment the body’s natural counter-reaction to the changes in brain cell-types that produced the dementia. Second, with edaravone to decrease free radicals, which are increased and causal in AD. Third, as described elsewhere, with one or two drugs from among pioglitazone, fluoxetine, and lithium, which address the brain cell-types whose changed functions cause the dementia. Insulin restores cerebral glucose, which is the main nutrient for brain neurons whose depletion is responsible for the dementia; and edaravone decreases ROS, which are intrinsic causes of neuropathology in AD. This combination of drugs is a potential cure for many patients with AD, and should be tested in a clinical trial.
first_indexed 2024-03-11T04:14:57Z
format Article
id doaj.art-2396795951784494aa76d4f2d529c579
institution Directory Open Access Journal
issn 2077-0383
language English
last_indexed 2024-03-11T04:14:57Z
publishDate 2023-04-01
publisher MDPI AG
record_format Article
series Journal of Clinical Medicine
spelling doaj.art-2396795951784494aa76d4f2d529c5792023-11-17T23:11:24ZengMDPI AGJournal of Clinical Medicine2077-03832023-04-01129315110.3390/jcm12093151Cure of Alzheimer’s Dementia in Many Patients by Using Intranasal Insulin to Augment an Inadequate Counter-Reaction, Edaravone to Scavenge ROS, and 1 or 2 Other Drugs to Address Affected Brain CellsJeffrey Fessel0Department of Medicine, University of California San Francisco, 2069 Filbert Street, San Francisco, CA 94123, USAThe goal of treatment for Alzheimer’s dementia (AD) is the restoration of normal cognition. No drug regimen has ever achieved this. This article suggests that curing AD may be achieved by combination therapy as follows. First, with intranasal insulin to augment the body’s natural counter-reaction to the changes in brain cell-types that produced the dementia. Second, with edaravone to decrease free radicals, which are increased and causal in AD. Third, as described elsewhere, with one or two drugs from among pioglitazone, fluoxetine, and lithium, which address the brain cell-types whose changed functions cause the dementia. Insulin restores cerebral glucose, which is the main nutrient for brain neurons whose depletion is responsible for the dementia; and edaravone decreases ROS, which are intrinsic causes of neuropathology in AD. This combination of drugs is a potential cure for many patients with AD, and should be tested in a clinical trial.https://www.mdpi.com/2077-0383/12/9/3151Alzheimer’s dementiacurenormal cognitionmolecular eventschanged functionsaugment counter-regulation
spellingShingle Jeffrey Fessel
Cure of Alzheimer’s Dementia in Many Patients by Using Intranasal Insulin to Augment an Inadequate Counter-Reaction, Edaravone to Scavenge ROS, and 1 or 2 Other Drugs to Address Affected Brain Cells
Journal of Clinical Medicine
Alzheimer’s dementia
cure
normal cognition
molecular events
changed functions
augment counter-regulation
title Cure of Alzheimer’s Dementia in Many Patients by Using Intranasal Insulin to Augment an Inadequate Counter-Reaction, Edaravone to Scavenge ROS, and 1 or 2 Other Drugs to Address Affected Brain Cells
title_full Cure of Alzheimer’s Dementia in Many Patients by Using Intranasal Insulin to Augment an Inadequate Counter-Reaction, Edaravone to Scavenge ROS, and 1 or 2 Other Drugs to Address Affected Brain Cells
title_fullStr Cure of Alzheimer’s Dementia in Many Patients by Using Intranasal Insulin to Augment an Inadequate Counter-Reaction, Edaravone to Scavenge ROS, and 1 or 2 Other Drugs to Address Affected Brain Cells
title_full_unstemmed Cure of Alzheimer’s Dementia in Many Patients by Using Intranasal Insulin to Augment an Inadequate Counter-Reaction, Edaravone to Scavenge ROS, and 1 or 2 Other Drugs to Address Affected Brain Cells
title_short Cure of Alzheimer’s Dementia in Many Patients by Using Intranasal Insulin to Augment an Inadequate Counter-Reaction, Edaravone to Scavenge ROS, and 1 or 2 Other Drugs to Address Affected Brain Cells
title_sort cure of alzheimer s dementia in many patients by using intranasal insulin to augment an inadequate counter reaction edaravone to scavenge ros and 1 or 2 other drugs to address affected brain cells
topic Alzheimer’s dementia
cure
normal cognition
molecular events
changed functions
augment counter-regulation
url https://www.mdpi.com/2077-0383/12/9/3151
work_keys_str_mv AT jeffreyfessel cureofalzheimersdementiainmanypatientsbyusingintranasalinsulintoaugmentaninadequatecounterreactionedaravonetoscavengerosand1or2otherdrugstoaddressaffectedbraincells